Zydus Lifesciences DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.76×	0.77×	0.78×	0.83×	0.81×
	0.91×	0.94×	0.98×	1.04×	0.83×
	23.1%	26.0%	26.4%	23.6%	18.2%
	0.61×	0.61×	0.70×	0.71×	0.64×
	1.77×	1.77×	1.41×	1.32×	1.31×
	17.4%	20.4%	19.9%	19.1%	10.2%
	19.7%	19.7%	0.7%	0.6%	11.4%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ZYDUSLIFE₹1,184.40

Zydus Lifesciences Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA DRREDDY CIPLA TORNTPHARM DIVISLAB MAXHEALTH APOLLOHOSP AUROPHARMAMcap ₹1.19L Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.81	0.83	0.78	0.77	0.76
Interest Burden (Pretax/EBIT) ×	0.83	1.04	0.98	0.94	0.91
EBIT Margin %	18.20	23.64	26.43	26.03	23.05
Asset Turnover ×	0.64	0.71	0.70	0.61	0.61
Financial Leverage (Assets/Equity) ×	1.31	1.32	1.41	1.77	1.77
ROE (5-step product, year-end total equity) %	10.16	19.12	19.86	20.39	17.36
ROE (owners' profit / average owners' equity) %	11.36	0.61	0.67	19.74	19.74

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.